Eteplirsen
Exondys (eteplirsen) is an oligonucleotide pharmaceutical. Eteplirsen was first approved as Exondys 51 on 2016-09-19. It is used to treat duchenne muscular dystrophy in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Exondys
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eteplirsen
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
EXONDYS 51 | Sarepta Therapeutics | N-206488 RX | 2016-09-19 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
exondys 51 | New Drug Application | 2020-07-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
duchenne muscular dystrophy | EFO_0000429 | D020388 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
ETEPLIRSEN, EXONDYS 51, SAREPTA THERAPS INC | |||
2023-09-19 | ODE-122 |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Eteplirsen, Exondys 51, Sarepta Theraps Inc | |||
9506058 | 2034-03-14 | U-1918, U-1919 | |
10337003 | 2034-03-14 | U-1918 | |
10364431 | 2034-03-14 | U-1918, U-1919 | |
RE47769 | 2029-02-02 | DP | |
RE48468 | 2028-10-27 | U-2097 | |
9243245 | 2028-10-27 | DP | U-2097, U-2098 |
RE47751 | 2025-06-28 | U-1918, U-2664, U-2673, U-2674 | |
9018368 | 2025-06-28 | DS, DP | |
10781451 | 2025-06-28 | DS, DP |
HCPCS
Code | Description |
---|---|
J1428 | Injection, eteplirsen, 10 mg |
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Duchenne muscular dystrophy | D020388 | 2 | 9 | 2 | — | — | 11 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ETEPLIRSEN |
INN | eteplirsen |
Description | Eteplirsen (oligonucleotide) |
Classification | Oligonucleotide |
Drug class | antisense oligonucleotides |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
PDB | — |
CAS-ID | 1173755-55-9 |
RxCUI | 1810569 |
ChEMBL ID | CHEMBL2108278 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB06014 |
UNII ID | AIW6036FAS (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Exondys - Sarepta Therapeutics, Inc.
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,288 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
84,306 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more